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In the UK vitamin B12 deficiency occurs in approximately 20% of adults aged >65 years. This
incidence is significantly higher than that among the general population. The reported incidence
invariably depends on the criteria of deficiency used, and in fact estimates rise to 24% and
46% among free-living and institutionalised elderly respectively when methylmalonic acid
is used as a marker of vitamin B12 status. The incidence of, and the criteria for diagnosis
of, deficiency have drawn much attention recently in the wake of the implementation of folic
acid fortification of flour in the USA. This fortification strategy has proved to be extremely
successful in increasing folic acid intakes pre-conceptually and thereby reducing the incidence
of neural-tube defects among babies born in the USA since 1998. However, in successfully
delivering additional folic acid to pregnant women fortification also increases the consumption
of folic acid of everyone who consumes products containing flour, including the elderly. It is
argued that consuming additional folic acid (as ‘synthetic’ pteroylglutamic acid) from fortified
foods increases the risk of ‘masking’ megaloblastic anaemia caused by vitamin B12 deficiency.
Thus, a number of issues arise for discussion. Are clinicians forced to rely on megaloblastic
anaemia as the only sign of possible vitamin B12 deficiency? Is serum vitamin B12 alone
adequate to confirm vitamin B12 deficiency or should other diagnostic markers be used
routinely in clinical practice? Is the level of intake of folic acid among the elderly (post-
fortification) likely to be so high as to cure or ‘mask’ the anaemia associated with vitamin B12
deficiency?
Folate: Vitamin B12 deficiency: Food fortification: Elderly
Interaction between folate and vitamin B12
There is no doubt that the debate surrounding the for-
tification of flour with folic acid is not without controversy.
One of the most controversial issues is the assertion
that folic acid may mask vitamin B12 deficiency in
the elderly. In order to appreciate some key aspects of
this controversy an understanding of the metabolic inter-
relationship between folic acid and vitamin B12 is required.
(Pteroylglutamic acid (PGA) is the form of folate used in
both supplements and fortified foods containing folic acid.
It is not normally found naturally occurring in foods.
The use of the term ‘folic acid’ throughout the present
article refers specifically to PGA.) Metabolic functions
of folate and vitamin B12 intersect in the methylation
cycle. One of the vitamin B12-dependent enzymes
(methionine synthase) functions in one of the folate cycles,
i.e. the methylation cycle (see Fig. 1). This cycle is
necessary to maintain the supply of the methyl donor
S-adenosylmethionine, and if it is interrupted it results in a
reduction in a wide range of methylated products. One
such important methylation process is that of myelin basic
protein; its reduction, as is seen in pernicious anaemia
(PA) and other causes of vitamin B12 deficiency, produces
sub-acute combined degeneration of the spinal cord.
Methylation defects are postulated to be the likely cause
of myelin damage and disturbed neurotransmitter meta-
bolism(1). Sub-acute combined degeneration of the spinal
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cord is one of the main presenting conditions in PA. The
other principal presenting condition in PA is a mega-
loblastic anaemia morphologically identical to that seen in
folate deficiency. The relationship between impairment of
the methylation cycle and a lack of DNA biosynthesis and
anaemia is explained by ‘the methyl trap hypothesis’(2).
This hypothesis suggests that when the folate cofactor
5-methyltetrahydofolate (THF) is formed, the enzyme
5,10-methyleneTHF reductase that forms the cofactor
cannot use it in the back reaction in vivo. Thus, the only
way for this folate cofactor to be recycled to THF (and
thus participate in DNA biosynthesis and allow cell
division), is through the vitamin B12-dependent enzyme
methionine synthase (see Fig. 1). When the activity of the
enzyme is compromized, as it would be in PA, the cellular
folates will become progressively trapped as 5-methylTHF.
As a result, the cell will suffer a form of folate deficiency,
in that it will have adequate folate but it will be trapped in
a form that cannot be used for DNA biosynthesis. The
consequence will be an anaemia identical to that seen in
true folate deficiency. Thus, in PA there will be a neuro-
pathy and/or anaemia(3). Treatment with vitamin B12, if
given intramuscularly, will reactivate methionine synthase,
allowing myelination to restart. The trapped folate will also
be released, thus allowing DNA synthesis and generation
of erythrocytes, redressing the anaemia. It is known that
treatment with high concentrations of folic acid will also
treat the anaemia but not the neuropathy in PA, because
when the synthetic form of folate (folic acid) enters the cell
it is first converted via dihydrofolate to THF (step ‘X’ in
Fig. 1). This process initially occurs outside the methyl
trap and can thus initiate DNA biosynthesis, so treating the
anaemia. While such folic acid is ultimately trapped as
5-methylTHF, if it is given continuously and in amounts
high enough to exceed the capacity of the intestinal
mucosal cells to convert it to 5-methylTHF, the folic acid
will keep DNA biosynthesis going and thus appear to
have treated the anaemia. However, administration of folic
acid cannot do anything to restart the methylation cycle,
blocked as it is at the vitamin B12-dependent enzyme
methionine synthase. Thus, the neuropathy will continue,
only to be diagnosed later when treatment with vitamin B12
may only partly reverse the nerve damage. This aspect is
discussed later (p. 554).
In addition to causing neuropathy and anaemia, even a
modest reduction in vitamin B12 status will cause elevation
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Fig. 1. Methylation cycle. DOPA, L-3,4-dihydroxyphenylalanine. (Adapted from Scott(85).)
Micronutrients through the life cycle 549
https://doi.org/10.1017/S0029665107005873
Downloaded from https:/www.cambridge.org/core. IP address: 92.237.134.134, on 16 Feb 2017 at 14:00:01, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
of plasma homocysteine because one of the principal
routes of homocysteine metabolism is to recycle homo-
cysteine to methionine via methionine synthase (see
Fig. 1).
Normal and abnormal vitamin B12 absorption
The impact of folate and vitamin B12 deficiencies in the
elderly cannot be underestimated. Among older partici-
pants of the National Health and Nutrition Examination
Survey III 14% of anaemia was caused by folate and/or
vitamin B12 deficiencies
(4). A further 20% were caused by
Fe deficiency combined with either folate or vitamin B12
deficiency. Thus, folate and/or vitamin B12 deficiencies
are the cause of approximately one-third (34%) of cases
of anaemia in the USA. Vitamin B12 deficiency is more
common among the elderly than among younger adults.
This higher prevalence can be more fully understood by
examining the mechanism by which dietary vitamin B12 is
absorbed. As Fig. 2 illustrates, vitamin B12 is released from
food within the lumen of the stomach when it is exposed to
gastric acid. Once liberated, vitamin B12 binds with high
affinity to haptocorrin (HC; also known as R protein),
which is primarily produced by the salivary glands. Since
HC has a high binding affinity at acidic pH, most dietary
vitamin B12 remains bound to HC in the stomach. Gastric
juice containing the vitamin B12–HC complex is then
emptied into the duodenum along with intrinsic factor (IF),
which is secreted by stimulated parietal cells. In the small
intestine vitamin B12 is released from the HC when it
comes into contact with bicarbonate, which along with the
pancreatic proteases hydrolyses the HC. The free vitamin
B12 then binds to IF and the vitamin B12–IF complex
moves within the intestinal fluid to the terminal ileum. In
the ileum the vitamin B12–IF complex binds to specific
receptors present on some enterocytes (a process that can
take place in the presence of Ca and a neutral pH). Endo-
cytosis follows and, once inside the cell, IF is degraded
and the vitamin B12 transferred to the mitochondria. Free
vitamin B12 is then transferred to secretory vesicles in the
basal portion of the ileal enterocyte, where it binds to
transcobalamin (TC) II. The vitamin B12–TC II complex is
liberated from the ileal enterocyte and enters the portal
circulation for storage in the liver or release into the
plasma for use by tissues(5,6).
Studies have suggested that an alternative route of vita-
min B12 absorption occurs when large doses are taken
orally (1000–2000mg)(7). This relatively inefficient route
of absorption probably occurs by means of passive diffu-
sion throughout the length of the small intestine(8). It is esti-
mated that only approximately 1% of the administered
dose is absorbed by this route(7). However, it is argued
that, in addition to folic acid, fortification of flour with
large doses of vitamin B12 might facilitate raising vitamin
B12 status in the elderly by passive diffusion and thus
allaying fears of undetected vitamin B12 deficiency. This
issue is discussed later (p. 556).
Vitamin B12 deficiency in the elderly
Causes
In the elderly adequate provision of vitamin B12 may be
limited by dietary supply or more commonly when one
or more steps in normal absorption, as described earlier,
are affected by disease(s). Malabsorption of cobalamin
becomes more frequent with age. In elderly patients vita-
min B12 deficiency is caused primarily by inadequate pro-
duction of IF causing malabsorption of food cobalamin and
PA. It also occurs in pancreatic insufficiency, because of a
lack of the enzymes needed to liberate cobalamin from the
cobalamin–HC complex(9). Cobalamin deficiency caused by
dietary deficiency or malabsorption (after release of cobal-
amin from food) is rarer(10,11). In American studies in which
a total of >200 patients with a proven cobalamin defi-
ciency were followed malabsorption of food cobalamin
was found to account for about 60–70% of the cases
among elderly patients and PA to account for 15–20% of
the cases(12–15). Other causes included dietary deficiency
(<5%), malabsorption (<5%), and hereditary cobalamin-
metabolism diseases (<1%).
First described in 1995(16), food-cobalamin malabsorp-
tion syndrome is characterized by the inability to release
cobalamin from food or from intestinal transport proteins,
particularly in the presence of hypochlorhydria in which
the absorption of ‘unbound’ cobalamin remains normal.
Malabsorption of food cobalamin is caused primarily by
gastric atrophy. Of patients >80 years >40% have gastric
atrophy that may or may not be related to Helicobac-
ter pylori infection(11,17). Other factors that contribute to
malabsorption of food cobalamin in the elderly include
chronic carriage of H. pylori and intestinal microbial pro-
liferation, which can be caused by antibiotic treatment(18),
long-term ingestion of biguandies (metformin)(19,20) and
antacids, including H2-receptor antagonists and proton
pump inhibitors(21,22); the latter being particularly pre-
valent among patients with Zollinger-Ellison syndrome(23),
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Fig. 2. Absorption of vitamin B12 in human subjects. ( ), Cobalamin
in food; ( ), haptocorrin (HC; also termed R protein); ( ), intrinsic
factor (IF); ( ), transcobalamin (TC). For a detailed explanation of
the absorption process, see p. 550.
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chronic alcoholism, surgery or gastric reconstruction (e.g.
bypass surgery for obesity) and partial pancreatic exo-
crine failure(14,24).
PA is a classic cause of cobalamin deficiency and one of
the most frequent among elderly patients; 20–50% of cases
according to two studies(25,26) and >15% in another patient
series(12–15). PA is an autoimmune disease characterized by
the destruction of the gastric mucosa, by a primarily cell-
mediated process(27). Gastric secretions are neutral to
slightly acidic even in the presence of gastrin (which nor-
mally increases acidity) and contain little or no IF(25,27,28).
Inadequate intake or nutritional deficiency of cobalamin
is rare among healthy adults in industrialized countries,
even among elderly adults; <5% according to one re-
port(14). It is limited to rare instances of patients on strict veg-
etarian diets and those who are already malnourished, such
as elderly patients, patients in institutions or patients in psy-
chiatric hospitals(29,30). US studies of the dietary intake of
the elderly have shown that £ 50% may have an insuffi-
cient intake of cobalamin (<2mg/d)(30). Such studies,
however, are extremely difficult to conduct because
they rely mainly on dietary histories(31). Moreover, even
if present, dietary deficiency does not result in sympto-
matic cobalamin deficiency until hepatic reserves are
exhausted.
Prevalence
Estimates among the elderly vary widely; from 5% (based
upon a low serum vitamin B12 concentration) among
institutionalized elderly adults in Germany, The Nether-
lands and Belgium(32) to 46% (based on multiple criteria
including serum vitamin B12 and methylmalonic acid
(MMA)) among institutionalized elderly adults in the
UK(33). The impact on estimates of prevalence of using
different criteria of deficiency can be illustrated by adapt-
ing data presented for a UK cohort of elderly adults(34).
Deficiency may be defined as having a serum vitamin B12
concentration below a cut-off (defined as frankly deficient)
or it may be defined further to include those with border-
line serum vitamin B12 and accompanying elevated levels
of MMA and/or homocysteine or as simply having bor-
derline serum vitamin B12 alone. When this analysis was
carried out on the data from the UK cohort(34) inadequate
status, including those with borderline serum vitamin B12,
was indicated among males; approximately one-quarter of
65–74 year olds and more than one-third of >75 year olds
could be defined as having a compromized status (see
Fig. 3).
Clinical symptoms and diagnosis
Cobalamin deficiency can take years to develop(35). Con-
sequently, the clinical symptoms of ‘classical’ cobalamin
deficiency, i.e. of severe megaloblastic anaemia combined
with neuropsychiatric symptoms, are rarely seen today(36).
However, vitamin B12 deficiency often goes unrecognized
because the initial clinical manifestations are subtle
and non-specific or are attributed to the normal ageing
process(37).
Detection and treatment of the early stages of cobalamin
deficiency is important(38), particularly in patients with
neuropsychiatric symptoms because they may fail to
respond if therapy is delayed(39). All patients with unex-
plained anaemia and/or unexplained neuropsychiatric
symptoms should ideally be examined for cobalamin defi-
ciency, because vitamin B12 deficiency can result in neu-
rological symptoms without haematological abnormalities.
An inverse relationship between the presence of neuro-
logical and haematological disease in vitamin B12 defi-
ciency has been reported(40); the higher the packed cell
volume, the worse the neuropathy. The early stages of
vitamin B12 deficiency will not lead to macrocytosis or
anaemia, because biochemical vitamin B12 deficit precedes
overt clinical deficiency with macro-ovalocytes and falling
Hb levels. Macrocytosis can be blocked by concurrent Fe
deficiency. The sensitivity of mean corpuscular volume
(MCV) to detect vitamin B12 deficiency is low, and many
patients with vitamin B12 deficiency will remain unnoticed
when the MCV is used to decide whether further evalu-
ation is necessary (see p. 552).
Haematological signs, especially macrocytic anaemia,
have traditionally been the cornerstone of diagnostics for
cobalamin status(41), but this position has been re-evaluated
during the last few years(42). In a review of the sequelae of
symptoms of vitamin B12 deficiency, it was commented
that anaemia is not present in all cases of vitamin B12
deficiency and discrete neuropsychiatric symptoms are
often the only signs(9). The concept that patients suffering
from cobalamin deficiency may have neuropsychiatric
symptoms without macrocytosis or anaemia was not
widely accepted until relatively recently(43). Even though
macrocytosis is considered a diagnostic, increased MCV
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Fig. 3. Variation in the interpretation of the incidence (%) of vitamin
B12 deficiency dependent on the criteria used (adapted from data for
a UK cohort of elderly adults(34)). Criterion A (///), serum vitamin B12
<150pM; criterion B ( ), serum vitamin B12 150–200pM and ele-
vated methylmalonic acid (MMA; >0.35mM) and elevated homo-
cysteine (>15mM); criterion C (&), serum vitamin B12 150–200 pM
and elevated MMA (>0.35mM) but normal homocysteine (<15mM);
criterion D (K), serum vitamin B12 150–200 pM and elevated
homocysteine (>15mM) but normal MMA (<0.35mM); criterion E ( ),
serum vitamin B12 150–200 pM and normal MMA and homocysteine.
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values are in most cases related to other conditions such as
drugs and alcohol abuse. Cobalamin and folate deficiencies
have been shown to be responsible for macrocytosis in
only about 6% of cases(44). Macrocytic anaemia is there-
fore not mandatory. Normocytic anaemia is seen if the
patient suffers from both cobalamin and Fe deficiencies.
Anaemia is seen in approximately 60% of patients with
cobalamin deficiency and neuropsychiatric symptoms
without anaemia are seen in £ 40% of patients(9). Thus, it
has been realized that neuropsychiatric illness may be the
only symptom of cobalamin deficiency and, importantly,
the neurological symptoms are considered of most concern
because they may fail to remit on therapy. Of patients with
neuropsychiatric illness approximately 80% have neuro-
logical symptoms, while 10% have psychiatric symptoms.
Stages of vitamin B12 deficiency
It is now commonly accepted that there are five stages
of vitamin B12 deficiency that between them encompass
the range from normal status to severe deficiency(45). The
earliest marker of a negative vitamin B12 balance is prob-
ably a low holoTC II concentration (<40 pg/ml). As the
deficiency progresses at least one of the metabolic markers
(most commonly MMA or less often homocysteine) will
also begin to rise as vitamin B12 becomes unavailable
for the associated chemical reactions. Further progression
will lead to an elevated MCV and, eventually, outright
anaemia.
Importantly, it is still not clear at which stage neuro-
logical damage first appears during decreasing vitamin B12
status. It is therefore not yet known when vitamin B12
deficiency becomes clinically important or, alternatively,
when the damage caused by such deficiency first occurs (as
soon as levels start to fall or as deficiency progresses). For
example, is neurological impairment reversible in patients
with decreased holoTC levels but normal levels of both
MMA and homocysteine? What is clear is that both MCV
and Hb reach levels that would be deemed clinically
abnormal only when vitamin B12 deficiency reaches a
very advanced stage. In clinical practice vitamin B12 test-
ing is often limited to patients who have an elevated
MCV, macrocytic anaemia or specific neurological symp-
toms(46).
Mean corpuscular volume as a diagnostic marker
The use of any marker as a diagnostic test for the detection
or exclusion of vitamin B12 deficiency is only useful if its
diagnostic accuracy is sufficiently high. For MCV to be a
good marker of vitamin B12 deficiency it would be expect-
ed that the low serum vitamin B12 level would have a
corresponding elevated MCV. However, according to data
from the National Diet and Nutrition Survey of those
aged >65 years(47) there is a marked discrepancy between
the numbers of the elderly who have low serum vitamin
B12 levels and numbers of those who have elevated
MCV(48).
MCV should not be relied on when screening for vita-
min B12 deficiency
(49,50). A systematic review has shown
that the MCV is far from perfect in terms of detecting or
excluding vitamin B12 deficiency, both for patients with
anaemia and those without anaemia(51). In fact, a con-
siderable number of patients who are vitamin B12 deficient
will remain unnoticed when the MCV is used to decide
which patients require further evaluation. Depending on
the population studied, £84% of cases may be missed.
Thus, the positive predictive value of elevated MCV is
low, whereas the negative predictive value is considered
rather high(51). Another study has concluded that con-
comitant evaluation of erythrocyte distribution width
could improve the diagnostic specificity of MCV(52). Of
the patients with an elevated MCV £55% will show
a vitamin B12 deficiency on further testing
(51). Thus,
MCV can be used to diagnose whether vitamin B12 defi-
ciency is more probable or less probable but cannot
be any more accurate. An elevated MCV justifies the
measurement of serum vitamin B12 and should not be the
only criterion used to rule out a diagnosis of vitamin B12
deficiency.
Haematological Markers and Vitamin B12 Deficiency
in the Elderly Study
The Haematological Markers and Vitamin B12 Deficiency
in the Elderly Study has confirmed previous findings that
MCV is not a good predictor of vitamin B12 status
(53).
The objective of the study was to assess the prevalence of
abnormal haematological markers among hospitalized
subjects with low serum vitamin B12 levels. In this analysis
serum folate and serum vitamin B12 were collated from all
subjects aged 65–85 years, who had these measurements
taken in a 6-month period (February–July 2003). Serum
ferritin, Hb, MCV and packed cell volume were included if
they had been measured within 4 d of serum folate and
vitamin B12 measurements. Data were divided into quin-
tiles of either serum folate or serum vitamin B12 and the
prevalence of anaemia was compared between quintiles.
The analysis shows that when subjects are stratified (into
quintiles) according to vitamin B12 status, MCV is as likely
to be elevated among those subjects with normal serum
vitamin B12 levels as it is among those with low serum
vitamin B12 levels (Fig. 4).
Biological markers of vitamin B12 status
It is now possible to diagnose early stages of deficiency,
even before the development of clinical symptoms(54), as a
result of the development of more specific and sensitive
diagnostic tests for cobalamin deficiency that can also
identify atypical forms of deficiency(55). However, accom-
panying the advent of these diagnostic tests is the risk of
their inappropriate use without reference to clinical signs
and symptoms. The advisability of using this approach has
been questioned and there certainly is a balance to be
struck between the risks of under-recognition of vitamin
B12 deficiency and potential over-diagnosis and over-
treatment of the disease(41).
The definition of, or diagnosis of, a disease based
purely on abnormal biochemical variables is, however,
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problematic(41) and invokes the danger of circular reason-
ing, especially if the diagnostic approach no longer
includes clinical criteria(54).
Serum cobalamin
The diagnostic utility of serum total cobalamin has been
questioned because total cobalamin in blood may not
accurately reflect intracellular vitamin B12 status in the
different tissues. As a result of the lack of specificity, the
lower cut-off limits for serum cobalamin have been
reduced at the expense of sensitivity(56). As a result, total
cobalamin in serum is now considered an unreliable indi-
cator of functional cobalamin status(32,57).
Furthermore, cobalamin may be strongly influenced
by folate deficiency(58). There are several conditions
under which artificially-high or -low total vitamin B12
concentrations can be measured, which greatly affect the
specificity of the serum vitamin B12 test in these pa-
tients(54). These conditions include: falsely-elevated serum
vitamin B12 caused by liver disease, myeloproliferative
disease, TC II deficiency, small intestinal bacterial over-
growth and haemolysis; falsely-low serum vitamin B12
caused by severe folate deficiency, severe Fe deficiency,
oral contraceptives, mild or severe HC deficiency and
myeloma.
Holotranscobalamin
Most cobalamin in serum is bound to HC. Only a minor
percentage, 20–30, is bound to TC, which is essential for
the transport of cobalamin from the ileum to the majority
of tissues and for cellular uptake through a receptor-
mediated process involving a specific receptor TC-R(59).
HoloTC may be a better marker of recently-absorbed cobal-
amin(60) and has been considered a more sensitive marker
of cobalamin status than total cobalamin(61).
Factors other than cobalamin status, however, may
affect the holoTC levels, and possibly its relationship with
the metabolic markers. These factors include a common
genetic polymorphism 776 (C776G) of the TC gene and
impaired renal function and liver disease(62–64), as well as
female sex hormones(65). The influence on holoTC of fac-
tors that are unrelated to cobalamin status may weaken the
utility of holoTC as a diagnostic marker. Moreover, the
fact that holoTC (like serum cobalamin) cannot be used to
monitor response to cobalamin supplementation is another
limitation of this marker. Further research is necessary
to evaluate the usefulness and limitations of holoTC in
clinical practice.
Methylmalonic acid
A lack of vitamin B12 (or more specifically, a lack of
hydroxocobalamin) leads to an accumulation of both
L-methylmalonyl-CoA and its precursor D-methylmalonyl-
CoA. Excess D-methylmalonyl-CoA is then converted
into MMA (measurable in both serum and urine). Overall,
the sensitivity of increased serum MMA in the diagnosis
of vitamin B12 deficiency appears to be greater than that of
serum homocysteine(57).
However, there are some major problems with the
measurement of MMA in terms of its application in clini-
cal practice. Measurement methods (GC–MS and HPLC)
are cumbersome and require expensive equipment. MMA
may also be increased in renal insufficiency and hypo-
volaemic states(66,67).
The greatest difficulty with MMA is how it may be
interpreted. The prevalence of high serum MMA in elderly
patients is substantially higher than either low serum vita-
min B12 levels or a clinically-evident deficiency state
(42,68),
which could mean that elevated MMA precedes low serum
vitamin B12 levels or that it is more sensitive. It is
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Fig. 4. Incidence of high mean corpuscular volume (MCV) and low
Hb in subjects aged 65–85 years participating in the Haematological
Markers and Vitamin B12 Deficiency in the Elderly Study
(53).
(A) Incidence of high MCV and low Hb by quintile of serum
vitamin B12. (K), Percentage with high MCV; (///), serum vitamin B12
(ng/l · 10 - 1); (&), percentage with low Hb. (B) Incidence of high
MCV and low Hb by quintile of serum folate(53). (K), Percentage
with high MCV; (///), serum folate (mg/l · 10) (&), percentage with
low Hb.
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recommended that elevated MMA be interpreted with
caution in the absence of further evidence of a deficiency
state(41,69).
Masking of vitamin B12 deficiency
The most important benefit of folic acid fortification of
staple foods (such as flour) is its ability to optimize folic
acid intakes without any need for the consumer to change
his/her food intake. Its accompanying disadvantage is the
provision of additional folic acid to those who do not need
it or who may in fact be in danger as a result of consuming
it. Therein lies the argument against folic acid fortification,
despite its establishment in USA since 1998 (a strategy to
reduce neural-tube defects (NTD)). The USA has chosen to
use PGA as the form of folic acid to add to flour and
cereals, possibly on the grounds of cost (PGA is markedly
cheaper than 5-methylTHF), and while early data suggest
that NTD incidence has decreased appreciably (a 19%
decrease since fortification was introduced(70)), a number
of arguments against fortification have been proposed
based on the metabolism of PGA by human subjects. Two
specific arguments exist that folic acid: (1) accelerates the
neurological damage caused by vitamin B12 deficiency; (2)
cures or ‘masks’ the anaemia of vitamin B12 deficiency,
thereby hiding or ‘masking’ a sign of deficiency on which
clinicians may be dependent for diagnosis.
Vitamin B12 deficiency and folic acid supplementation
and accelerated neurological damage
Accepting that vitamin B12 deficiency may only manifest
clinically in some patients as neurological damage, it has
been suggested that administration of high doses of folic
acid might have precipitated neurological degeneration. It
is now not possible to prove whether or not there is an
increased rate of sub-acute combined degeneration of the
spinal cord, or whether the neuropathy is made more
severe as a result of giving folic acid to vitamin B12-
deficient individuals. Such a study would be unethical.
Although folic acid is not toxic to normal individuals even
in large doses, it might appear to be neurotoxic in the
special circumstances of vitamin B12 deficiency. In gen-
eral, it is agreed that there are no data that demonstrate that
folic acid is harmful to the nervous system in individuals
with vitamin B12 deficiency at doses of £ 1 mg folic acid/d
in the short term. However, folic acid can correct the
anaemia of vitamin B12 deficiency in some patients even at
doses <1 mg/d(48). This outcome could alter the presen-
tation of vitamin B12 deficiency in the population (with a
larger proportion of patients presenting with altered sen-
sation and a smaller proportion presenting with symptoms
of anaemia). It is not possible to predict the effect on the
incidence of irreversible vitamin B12 neuropathy, although
arguments can be put forward to suggest it might increase
as a result of a delay in the diagnosis, which can depend on
detecting anaemia. Any general policy to increase dietary
folic acid consumption should require vigilance in relation
to the incidence, prevalence and presentation of vitamin
B12 neuropathy in the community to determine whether
these data change.
Effects of folic acid on reticulocytosis in vitamin B12
deficiency
At high doses (yet to be determined, but in healthy adults
possibly >300mg in a bolus dose(71)), the metabolic
handling of PGA changes during the absorption process. A
non-saturable transport mechanism involving passive dif-
fusion of this unaltered vitamin allows the passage of
PGA from the gut, into the portal circulation and into cells
(as unaltered PGA). The uptake of the unaltered vitamin
may lie at the centre of the argument against fortification.
It is well recognized that both 5-methylTHF (the pre-
dominant circulating form of folate) and vitamin B12 are
required to regenerate THF (the substrate for the formation
of 5-methyleneTHF) and subsequently for DNA pyri-
midine synthesis (see Fig. 1). Thus, during vitamin B12
deficiency this cascade is inhibited and a megaloblastic
anaemia may develop (as a result of inadequate DNA
synthesis for erythrocyte cell division); an anaemia that is
indistinguishable from that associated with folate defi-
ciency. However, unlike 5-methylTHF, PGA, can bypass
the vitamin B12-dependent pathway and is converted to
THF by another route (step ‘X’ in Fig. 1). Thus, during
vitamin B12 deficiency and in the presence of unaltered
PGA substrates are still available for DNA pyrimidine
synthesis. Thus, normal reticulocytosis is achieved despite
vitamin B12 deficiency. Although it was thought that
folic acid might exacerbate vitamin B12 deficiency and
its symptoms, it is probably not the case(72). However, if
the diagnosis of vitamin B12 deficiency is dependent on the
observation of clinical symptoms of anaemia, or morpho-
logical changes in erythrocyte cells, which it often is,
then folic acid may ‘mask’ the underlying vitamin B12
deficiency by allowing normal pyrimidine synthesis to
progress. Unfortunately, the (irreversible) neurological
symptoms would also progress untreated. The recent
Department of Health report on folate in health has
recommended that folic acid fortification is desirable for
the prevention of NTD, but is less emphatic about the risks
to the elderly (particularly among the elderly with vitamin
B12 deficiency)
(48). Subsequently, fortification was not
recommended in the UK by the Food Standards Agency(73),
citing that ‘further evidence on the impact on older people
needs to be considered, including the extent to which it
would be possible to put in place effective surveillance for
vitamin B12 deficiency’. However, in May 2007 the Food
Standards Agency Board agreed unanimously that ‘man-
datory fortification’ with folic acid should be introduced,
alongside controls on voluntary fortification and advice on
the use of supplements. (The Scientific Advisory Com-
mittee for Nutrition report underpinning this decision(74) is
discussed later (p. 555).)
Few systematic data exist in relation to the level of folic
acid intake required to mask vitamin B12 deficiency
(75).
The majority of available information relates to early case
reports of folic acid therapy (mostly high dose, e.g.
‡5 mg/d) for the treatment of PA(73). In general, the data
taken from these reports have suggested that
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supplementation with £ 1 mg folic acid/d is safe in this res-
pect (i.e. does not alleviate vitamin B12-associated anaemia
in the majority of subjects). The effects of doses between 1
and 5 mg folic acid/d are unclear, whilst supplementation
with ‡5 mg folic acid/d is reported to reverse the
haematological signs of vitamin B12 deficiency in ‡50%
of subjects(72,76,77).
Current data are therefore equivocal as to the impact of
PGA (and dose) on haematological responses, and there
are no data to assess the dose–response relationship
between PGA intake and haematological responses. Data
on the effects of low doses of folic acid in vitamin B12
deficiency are very limited, but suggest that approximately
half the patients who are vitamin B12 deficient will show
a reticulocytosis after the administration of 0.4 mg folic
acid/d(77). It has been suggested that the upper limit of
intake should be set at 1 mg folic acid/d(78).
It should be stressed that so-called ‘masking’ of the
anaemia of PA is not thought to occur at concentrations
of folate found in food, or at intakes of the synthetic
form of folic acid at the usual RDA levels of 200mg/d
or 400mg/d(71). However, ‘masking’ definitely occurs at
high concentrations of folic acid (>1000mg/d). The latter
becomes a concern when it is proposed to add synthetic
folic acid to the diet by way of fortification of a dietary
staple such as flour. The concern is that if folic acid is
added to have the desirable effect of reducing NTD (and/or
lowering plasma homocysteine), those individuals on high
flour intakes could inadvertently become exposed to very
high levels of folic acid. Included among these individuals
are elderly adults whose timely diagnosis of PA (via pre-
sentation as the anaemia) might be delayed. This delay in
diagnosis could allow the neuropathy to progress to such
an extent that when it is eventually diagnosed it is partly or
largely irreversible.
Folic Acid Supplementation in Vitamin B12
Deficiency Study
Monitoring and tracking the effects of folic acid fortifica-
tion on the masking of anaemia is less easy in a population
with access to fortified foods such as the USA. Mandatory
folic acid fortification does not exist in the UK, and it
therefore provides an ideal environment for carrying out a
controlled intervention. The Folic Acid Supplementation in
Vitamin B12 Deficiency Study was conducted to assess the
impact of folic acid supplementation on the incidence of
anaemia in subjects who have borderline vitamin B12
deficiency. In populations such as in Northern Ireland
where there is limited voluntary fortification elderly adults
who consume fortified foods can be easily identified by
screening questionnaire. Those individuals who consumed
neither folic acid supplements nor fortified foods qualified
to participate in the intervention. The study recruited
elderly subjects with borderline vitamin B12 deficiency
(who would not usually be referred for vitamin B12 therapy
in a clinical setting) and randomly assigned them to
receive either placebo or 400mg folic acid/d for 24 weeks.
The primary objective was to assess the effect of sup-
plementation on haematological markers and thereby as-
certain whether additional folic acid masks anaemia as
defined by MCV. Vitamin B12 and folate status were also
monitored throughout the intervention. This study has been
completed and its results will provide analysis of the
effects on haematological markers (including MCV) of a
controlled folic acid intervention in elderly adults with
borderline vitamin B12 deficiency.
Potential impact of fortification among the elderly
Modelling of the UK National Diet and Nutrition Survey
of the elderly(47) has been completed by the Committee on
Medical Aspects of Health Policy(48) and it was found that
intakes of PGA would be >1 mg/d in <1% of those >50
years (at fortification levels of 2.4 mg/kg). However, these
estimates are based on modelling of recorded food intakes
that may themselves be underestimated. Hence, the data
generated from modelling exercises must be treated with
caution as they are probably an estimate of the minimal
possible effect. In addition, modelling only estimates the
additional planned folic acid intake based on theoretical
targets and does not therefore take account of actual addi-
tional intakes that would almost certainly be higher as a
result of overage. However, in 2006 the Scientific Advi-
sory Committee for Nutrition completed a subsequent
modelling exercise of the UK National Diet and Nutrition
Survey data(74). Their results indicate that fortification
would have a less marked impact on increasing folic acid
intakes than that predicted by the Committee on Medical
Aspects of Health Policy analysis. The Scientific Advisory
Committee for Nutrition attribute higher predictions of the
Committee on Medical Aspects of Health Policy to not
taking processing losses into account and overestimating
the percentage of flour in flour products. The Scientific
Advisory Committee for Nutrition conclude from their
analysis that mandatory fortification at levels as high as
3.0 mg/kg would in fact reduce the numbers of individuals
at risk of consuming >1 mg folic acid/d (if the availab-
ility of both voluntary fortification of foods with folic acid
and non-prescription folic acid supplements were to dis-
continue).
Impact of fortification in the USA
Fortification in the USA was estimated to provide an
average of an additional 0.1 mg folic acid/d, although
published data suggest that in fact actual intakes are twice
this amount, at an average additional 0.2 mg/d(79,80). There
are virtually no data on the Hb response or risk of devel-
oping neuropathy at such doses(77).
Notwithstanding the lack of data on folic acid dose and
haematological response, optimism for the safety of for-
tification for the elderly in the USA has been proposed on
the basis of a recent analysis(81). This analysis tracked the
incidence of anaemia among subjects with low vitamin B12
status from the period pre-fortification until 2 years after
mandatory fortification was introduced in the USA. They
found no obvious trend towards increased incidence
of ‘masked’ anaemia among those with low vitamin B12
status. This analysis has both merits and limitations. For-
tunately, results are based on clinical observations and
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therefore reflect the impact of actual intakes of additional
folic acid among the US elderly. They are not therefore
dependent on modelling data. However, the tracking
and monitoring period included was only 5 years post-
fortification and possibly not long enough to measure true
long-term trends. While this study is considered by some
to be a positive indication for implementation of fortifica-
tion, caution should be exercised about these conclusions
on the basis of the limitations of the analysis.
Folic acid fortification: pros and cons for the elderly
Notwithstanding the potential masking effect of folic acid,
there may be some potential benefits of fortification for the
elderly, not least the ability for fortification to improve
folate status. The majority of the elderly who are folate
deficient are not vitamin B12 deficient (approximately
90%(34)). There is no definitive evidence that folic acid
causes accelerated neurological damage. Fortification
would deliver folic acid in smaller multiple doses
throughout the day and there is no evidence to suggest that
folic acid consumed in this way by the elderly would lead
to free folic acid accumulating in serum. Finally, where a
system exists for efficiently monitoring and screening for
vitamin B12 deficiency, the issue of masking would not
need to be addressed.
On the other hand, there are some potential detrimental
effects of fortification. In the absence of an efficient system
for screening the elderly population for vitamin B12 defi-
ciency, the potential for PGA to mask vitamin B12 defi-
ciency and the minimum dose at which deficiency occurs
has not yet been defined. Furthermore, there has been no
conclusion about whether smaller doses spread across the
day are safe. In fact, recent evidence suggests that in some
population groups they may not be safe(82), as studies in
pregnant women have suggested that free folic acid levels
in serum are sustained to a greater extent when multiple
doses are given throughout the day than when a single dose
is given once daily. Evidence that additional folic acid
could lower the risk of certain cancers and CVD (diseases
that have a high incidence among the elderly) is still
equivocal(74).
Vitamin B12 fortification
It has been argued that masking of vitamin B12 deficiency
is a red herring and could be simply overcome by simul-
taneous fortification with vitamin B12. The debate about
fortification would be less complicated if combined vita-
min B12–folic acid fortification was a solution to the
potential effect of masking of vitamin B12 deficiency by
folic acid. However, adding vitamin B12 would be an
ineffective strategy. In most cases of vitamin B12 defi-
ciency the cause is related to malabsorption(74), and there-
fore oral vitamin B12 would not help to improve status.
Even if a large dose was given only 1% of oral vitamin
B12 could be absorbed by passive diffusion. High doses of
vitamin B12 also have the effect of turning flour yellow.
The dose of vitamin B12 that would need to be added
would therefore be prohibitive.
Treatment and conclusions
There is a danger that excitement about the benefits of folic
acid fortification to one subset of the population (babies at
risk of NTD) may obscure the clear necessity to assess its
possible drawbacks to another population group (the
elderly). Folic acid fortification is undoubtedly a way for-
ward to prevent NTD, but only if its implementation also
assumes the responsibility to screen for individuals at risk
of vitamin B12 deficiency.
Currently, there is neither an independent gold standard
nor a reference method for unequivocal characterization
of vitamin B12 deficiency
(24). Moreover, there is no agree-
ment on how to treat (in relation to formulation, dosage,
cobalamin preparation, intensity and duration of treat-
ment), or on when and how to monitor the effects of treat-
ment(83).
It has been suggested that it may be possible to cate-
gorize ‘at-risk’ elderly for vitamin B12 deficiency using
haematological variables; measured routinely in clinical
practice. However, when this hypothesis was tested using
clinical data from a UK hospital, it was found that
regardless of the comparisons made (>70 years old v. <70
years old; anaemic v. non-anaemic, macrocytosis v. nor-
mocytosis; macrocytosis v. microcytosis; normocytosis v.
microcytosis) there was no relationship between the pre-
valence of abnormal haematology and vitamin B12 defi-
ciency(84).
In principle, to prevent irreversible neurological damage
it may be justifiable to use prophylactic cobalamin treat-
ment only on the basis of early biochemical signs. This
approach poses particular demands on the specificity and
sensitivity of diagnostic tests(56). Some neurological sym-
ptoms may become irreversible 1 year after the first
clinical signs(54).
Conclusions and recommendations
As long as there still remains a lack of a reliable clinical
test for the diagnosis of true vitamin B12 deficiency, any
fortification programme should be accompanied by appro-
priate systems to ensure that the elderly at risk of vitamin
B12 deficiency are identified. As concluded by Scientific
Advisory Committee for Nutrition, the issue of overage
needs to be given careful consideration(74). This approach
would appear to be the most balanced way forward.
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